CN101678112B - 用于递送治疗剂的方法和组合物 - Google Patents

用于递送治疗剂的方法和组合物 Download PDF

Info

Publication number
CN101678112B
CN101678112B CN200880005593.3A CN200880005593A CN101678112B CN 101678112 B CN101678112 B CN 101678112B CN 200880005593 A CN200880005593 A CN 200880005593A CN 101678112 B CN101678112 B CN 101678112B
Authority
CN
China
Prior art keywords
pharmaceutical composition
therapeutic agent
composition
polyethylene glycol
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880005593.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN101678112A (zh
Inventor
S·吉苏拉森
J·阿普
R·戈德瑞
M·E·拉斯蒂
G·G·普拉辛斯基
M·亚兹迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HASKOLI ISLANDS
Hananja ehf
Ikano Therapeutics Inc
Original Assignee
HASKOLI ISLANDS
Hananja ehf
Intranasal Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HASKOLI ISLANDS, Hananja ehf, Intranasal Therapeutics Inc filed Critical HASKOLI ISLANDS
Priority to CN201610672083.8A priority Critical patent/CN106389330A/zh
Priority to CN201610674407.1A priority patent/CN106420614A/zh
Publication of CN101678112A publication Critical patent/CN101678112A/zh
Application granted granted Critical
Publication of CN101678112B publication Critical patent/CN101678112B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880005593.3A 2007-01-19 2008-01-18 用于递送治疗剂的方法和组合物 Active CN101678112B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201610672083.8A CN106389330A (zh) 2007-01-19 2008-01-18 用于递送治疗剂的方法和组合物
CN201610674407.1A CN106420614A (zh) 2007-01-19 2008-01-18 用于递送治疗剂的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8593/2007 2007-01-19
IS8593 2007-01-19
PCT/US2008/051466 WO2008089426A2 (en) 2007-01-19 2008-01-18 Methods and compositions for the delivery of a therapeutic agent

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201610674407.1A Division CN106420614A (zh) 2007-01-19 2008-01-18 用于递送治疗剂的方法和组合物
CN201610672083.8A Division CN106389330A (zh) 2007-01-19 2008-01-18 用于递送治疗剂的方法和组合物

Publications (2)

Publication Number Publication Date
CN101678112A CN101678112A (zh) 2010-03-24
CN101678112B true CN101678112B (zh) 2016-08-31

Family

ID=39512543

Family Applications (3)

Application Number Title Priority Date Filing Date
CN200880005593.3A Active CN101678112B (zh) 2007-01-19 2008-01-18 用于递送治疗剂的方法和组合物
CN201610674407.1A Pending CN106420614A (zh) 2007-01-19 2008-01-18 用于递送治疗剂的方法和组合物
CN201610672083.8A Pending CN106389330A (zh) 2007-01-19 2008-01-18 用于递送治疗剂的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201610674407.1A Pending CN106420614A (zh) 2007-01-19 2008-01-18 用于递送治疗剂的方法和组合物
CN201610672083.8A Pending CN106389330A (zh) 2007-01-19 2008-01-18 用于递送治疗剂的方法和组合物

Country Status (11)

Country Link
EP (2) EP3150230A1 (https=)
JP (5) JP5877939B2 (https=)
CN (3) CN101678112B (https=)
AU (1) AU2008206105B2 (https=)
CA (1) CA2676010C (https=)
DK (1) DK2121025T3 (https=)
ES (1) ES2611995T3 (https=)
HU (1) HUE031463T2 (https=)
IL (1) IL199904A (https=)
PL (1) PL2121025T3 (https=)
WO (1) WO2008089426A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
GB2481407B (en) * 2010-06-22 2012-05-23 Special Products Ltd A rapid onset liquid midazolam composition for buccal administration
MY194947A (en) * 2011-05-13 2022-12-27 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
WO2019049145A1 (en) * 2017-09-11 2019-03-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. COMPOSITIONS AND METHODS FOR NASAL BRAIN MEDICATION ADMINISTRATION FOR SYSTEMIC EFFECT
JP2019099557A (ja) * 2017-11-28 2019-06-24 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
WO2019226753A1 (en) 2018-05-25 2019-11-28 Ucb Biopharma Sprl Benzodiazepine formulations
CN111388481A (zh) * 2020-03-20 2020-07-10 浙江美华鼎昌医药科技有限公司 一种咪达唑仑和丙戊酸钠的药物组合物及其制备方法
CN114588116B (zh) * 2020-12-04 2024-03-15 四川科瑞德制药股份有限公司 磷苯妥英钠固体组合物、冻干方法、及其用途
CN113274482B (zh) * 2021-06-07 2023-09-05 穆琳 缩宫素或其衍生物在制备治疗或改善贫乳的制剂中的用途以及组合物
WO2024142091A1 (en) * 2022-12-26 2024-07-04 Cipla Limited Stable aqueous injectable formulation of flucytosine
CN119488471A (zh) * 2023-08-17 2025-02-21 纳索菲德(上海)制药技术有限公司 一种尼莫地平鼻脑递释制剂、其制备方法及其用途
WO2025115019A1 (en) * 2023-11-30 2025-06-05 Padagis Israel Pharmaceuticals Ltd. Stable nitroglycerin formulations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000152A1 (en) * 1996-07-03 1998-01-08 Alza Corporation Non-aqueous protic peptide formulations
WO2001012718A1 (en) * 1999-08-14 2001-02-22 Samyang Corporation Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof
US20020037319A1 (en) * 1999-11-08 2002-03-28 Alan Drizen Drug preparations
US20050137164A1 (en) * 2003-09-22 2005-06-23 Moshe Arkin Diclofenac compositions for the treatment of skin disorders
US20050244517A1 (en) * 2003-11-05 2005-11-03 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153689A (en) 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
US4863720A (en) * 1986-03-10 1989-09-05 Walter Burghart Pharmaceutical preparation and methods for its production
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
ES2117642T3 (es) 1990-05-10 1998-08-16 Bechgaard Int Res Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
GB9125699D0 (en) 1991-12-03 1992-01-29 Glaxo Group Ltd Device
US5897880A (en) * 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
MXPA02001612A (es) * 1999-07-26 2003-10-14 Sk Corp Composiciones anti-convulsivas transnasales y procedimiento modular.
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
DE19940236A1 (de) 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
EP1315533A4 (en) 2000-08-15 2007-06-27 Univ Kentucky Res Found PROGRAMMABLE MULTI-DOSE DEVICE FOR INTRANASAL MEDICINE ADMINISTRATION
JP2005531570A (ja) * 2002-05-23 2005-10-20 ユーエムディー， インコーポレイテッド 貫粘膜薬物送達及び凍結保護のための組成物及び方法
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
JP2007070225A (ja) * 2003-07-25 2007-03-22 Yukako Fujinaga クロストリジウム属菌由来成分を含む医薬製剤
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
JP4746856B2 (ja) * 2004-08-12 2011-08-10 三笠製薬株式会社 ピラゾロン系製剤
JP5144277B2 (ja) * 2005-01-14 2013-02-13 カムルス エービー 局所用生体付着性製剤
US20070021411A1 (en) * 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CA2669705A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000152A1 (en) * 1996-07-03 1998-01-08 Alza Corporation Non-aqueous protic peptide formulations
WO2001012718A1 (en) * 1999-08-14 2001-02-22 Samyang Corporation Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof
US20020037319A1 (en) * 1999-11-08 2002-03-28 Alan Drizen Drug preparations
US20050137164A1 (en) * 2003-09-22 2005-06-23 Moshe Arkin Diclofenac compositions for the treatment of skin disorders
US20050244517A1 (en) * 2003-11-05 2005-11-03 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents

Also Published As

Publication number Publication date
DK2121025T3 (en) 2017-01-30
JP5877939B2 (ja) 2016-03-08
CN106389330A (zh) 2017-02-15
WO2008089426A3 (en) 2009-02-12
JP2017155060A (ja) 2017-09-07
HUE031463T2 (en) 2017-07-28
JP2017048250A (ja) 2017-03-09
EP2121025A2 (en) 2009-11-25
EP3150230A1 (en) 2017-04-05
JP2016029117A (ja) 2016-03-03
IL199904A (en) 2014-07-31
JP2010516696A (ja) 2010-05-20
AU2008206105B2 (en) 2014-04-03
CA2676010C (en) 2016-05-17
EP2121025B1 (en) 2016-11-02
JP6295314B2 (ja) 2018-03-14
JP2013231089A (ja) 2013-11-14
AU2008206105A1 (en) 2008-07-24
WO2008089426A2 (en) 2008-07-24
CA2676010A1 (en) 2008-07-24
IL199904A0 (en) 2010-04-15
JP6084277B2 (ja) 2017-02-22
CN106420614A (zh) 2017-02-22
PL2121025T3 (pl) 2017-09-29
ES2611995T3 (es) 2017-05-11
CN101678112A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
CN101678112B (zh) 用于递送治疗剂的方法和组合物
US10052333B2 (en) Methods and systems for the delivery of a therapeutic agent
JP2017155060A5 (https=)
Jadhav et al. Nasal drug delivery system-factors affecting and applications
JP3219096B2 (ja) ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤
JPH0651620B2 (ja) ニトログリセリンを含む噴射ガス不使用のエアロゾル組成物、およびその製造方法
KR20150063567A (ko) 고형 제형
JP2011515485A (ja) ロフェキシジンを経粘膜送達するための組成物およびその方法
HK1230483A (en) Methods and compositions for the delivery of a therapeutic agent
HK1230483A1 (en) Methods and compositions for the delivery of a therapeutic agent
AU2013203271B2 (en) Methods and compositions for the delivery of a therapeutic agent
AU2018202245A1 (en) Methods and compositions for the delivery of a therapeutic agent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant